Skip to content

REGENXBIO Inc Sustainability Reports

REGENXBIO Inc. is a clinical-stage biotechnology company focused on the development, commercialization, and licensing of gene therapies using its proprietary adeno-associated virus delivery platform.

Sector: Manufacturing

Country: United States

Exchange: Nasdaq

LEI: 549300EOES47LATSET33

FIGI: BBG007Z9V5C7

3 reports from 2017 to 2023